A multicentre, randomised, controlled, open-label pilot study on the feasibility of discontinuation of adalimumab in established patients with rheumatoid arthritis in stable clinical remission.

RMD Open · 2016 · PMC4716561 · PMID 26819752

Europe PMC DOI

hedged sentence

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

did not reach statistical significancep=0.07so close (0.05 < p ≤ 0.1)

Survival curves suggested higher flare-free survival over time in patients randomised to continue treatment with ADA, although the difference did not reach statistical significance (p=0.07; figure 4 ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.